301 results on '"Ioka, T."'
Search Results
2. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
3. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
4. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer
5. # 1391 EUS-guided fiducial marker placement for neoadjuvant chemoradiotherapy for resectable pancreatic cancer
6. 1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
7. P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement
8. Management of complications after partial hepatic resection in a hemodialysis patient with severe hepatomegaly caused by autosomal dominant polycystic kidney disease
9. Modification of low density lipoprotein potentiates its inhibitory effect on catecholamine secretion in cultured bovine adrenal medullary cells
10. 128P Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
11. Hypertension Induced by Erythropoietin Has a Correlation With Truncated Erythropoietin Receptor mRNA in Endothelial Progenitor Cells of Hemodialysis Patients
12. Lower-extremity venous stasis during laparoscopic cholecystectomy as assessed using color Doppler ultrasound
13. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells
14. Confirmation of a “safety zone” by intraoperative cholangiography during laparoscopic cholecystectomy
15. Confirmation of a ``safety zone'' by intraoperative cholangiography during laparoscopic cholecystectomy
16. Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
17. Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
18. Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: A prospective observational study (PRELUDE study)
19. Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer
20. Phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer
21. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
22. A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)
23. The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302)
24. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
25. 274TiP A randomized phase 2 study of nanoliposomal irinotecan (nal-IRI, BAX2398)-containing regimen in Japanese patients with metastatic pancreatic adenocarcinoma (mPAC)
26. 145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
27. 132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
28. 723P - Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: A prospective observational study (PRELUDE study)
29. 714P - Phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer
30. 704P - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer
31. The Phase 1 Study of Concurrent Chemoradiation Therapy With Gemcitabine and Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma Patients
32. Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106
33. 762P - A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)
34. 615O - Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
35. P-119 - The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302)
36. 409 Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies against apolipoprotein-AII isoforms
37. 2382 A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers
38. P0371 : A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)
39. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
40. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer
41. 621PD - Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106
42. PP015—Chronotherapy with docetaxel, cisplatin, and 5-fluorouracil (5-FU) in patients with oral squamous cell carcinoma
43. Safety and Effectiveness of Gemcitabine in 855 Patients with Pancreatic Cancer under Japanese Clinical Practice Based on Post-marketing Surveillance in Japan
44. Hepatobiliary Pancreatic Cancer: Cutting-Edge Drug Therapy
45. Retrospective Analysis of the Difference of Prognosis between Unresectable and Recurrent Biliary Tract Cancer: Kansai Hepatobiliary Oncology Group (KHBO) 1001
46. A Multi-Center Phase II Study of Intra-Arterial Chemotherapy of a Fine-Powder Formulation of Cisplatin in Patients with Advanced Intrahepatic Cholangiocarcinoma
47. Relations of QOL to Tumor Response and Adverse Events in Unresectable advanced Pancreatic Cancer Patients in the Gest Study
48. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study.
49. Concurrent chemoradiotherapy with gemcitabine and S-1 for unresectable locally advanced pancreatic adenocarcinoma: A phase I study.
50. A Randomized Phase II Study of Gemcitabine 1000mg/msq and Concurrent Radiotherapy Comparing Gemcitabine Alone for Unresectable Locally Advanced Pancreatic Adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.